258 related articles for article (PubMed ID: 23984805)
1. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations.
Haznedaroglu IC
Expert Opin Pharmacother; 2013 Oct; 14(15):2005-10. PubMed ID: 23984805
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
3. Cessation of tyrosine kinase inhibitors in patients with chronic-phase chronic myelogenous leukemia following durable complete molecular response: a single center facing the dilemma.
Iliakis T; Papadopoulou V; Diamantopoulos PT; Panayiotidis P; Zervakis K; Giannakopoulou N; Tilimidos G; Angelopoulou M; Siakantaris MP; Pangalis G; Mantzourani M; Variami E; Viniou NA
Anticancer Res; 2013 Aug; 33(8):3509-14. PubMed ID: 23898127
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
Firwana B; Sonbol MB; Diab M; Raza S; Hasan R; Yousef I; Zarzour A; Garipalli A; Doll D; Murad MH; Al-Kali A
Int J Cancer; 2016 Mar; 138(6):1545-53. PubMed ID: 26455714
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
Khoury HJ; Bixby DL
Leuk Lymphoma; 2015 Mar; 56(3):568-76. PubMed ID: 24884315
[TBL] [Abstract][Full Text] [Related]
7. Current perspectives for the treatment of chronic myeloid leukemia.
Aladağ E; Haznedaroğlu İC
Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
[TBL] [Abstract][Full Text] [Related]
8. A review of the European LeukemiaNet recommendations for the management of CML.
Baccarani M; Castagnetti F; Gugliotta G; Rosti G
Ann Hematol; 2015 Apr; 94 Suppl 2():S141-7. PubMed ID: 25814080
[TBL] [Abstract][Full Text] [Related]
9. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Jabbour E; Kantarjian HM; O'Brien S; Shan J; Quintás-Cardama A; Garcia-Manero G; Rios MB; Cortes JE
J Clin Oncol; 2011 Nov; 29(32):4260-5. PubMed ID: 21990394
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
Pan P; Wang L; Wang Y; Shen L; Zheng P; Bi C; Zhang A; Lv Y; Xue Z; Sun M; Sun C; Li J; Jin L; Yao Y
Acta Haematol; 2020; 143(3):204-216. PubMed ID: 31514197
[TBL] [Abstract][Full Text] [Related]
11. Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?
Patel AB; Wilds BW; Deininger MW
Expert Rev Hematol; 2017 Jul; 10(7):659-674. PubMed ID: 28511567
[TBL] [Abstract][Full Text] [Related]
12. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
13. Integrating current treatment options for TKI-resistant chronic myeloid leukemia.
Radich JP; Shah NP; Mauro MJ
Clin Adv Hematol Oncol; 2014 Jul; 12(7 Suppl 13):3-17, 1. PubMed ID: 25768408
[TBL] [Abstract][Full Text] [Related]
14. Drug Therapy in the Progressed CML Patient with multi-TKI Failure.
Haznedaroglu IC
Mediterr J Hematol Infect Dis; 2015; 7(1):e2015014. PubMed ID: 25745541
[TBL] [Abstract][Full Text] [Related]
15. Evolution of therapies for chronic myelogenous leukemia.
Santos FP; Kantarjian H; Quintás-Cardama A; Cortes J
Cancer J; 2011; 17(6):465-76. PubMed ID: 22157290
[TBL] [Abstract][Full Text] [Related]
16. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
García-Gutiérrez V; Breccia M; Jabbour E; Mauro M; Cortes JE
J Hematol Oncol; 2022 Jul; 15(1):90. PubMed ID: 35818053
[TBL] [Abstract][Full Text] [Related]
17. Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.
Akard LP; Bixby D
Leuk Lymphoma; 2016 May; 57(5):1002-14. PubMed ID: 26726949
[TBL] [Abstract][Full Text] [Related]
18. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
19. A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Rohon P; Faber E; Divoka M; Rozmanova S; Friedecky D; Jarosova M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun; 157(2):181-8. PubMed ID: 22660209
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]